Atovaquone Powder
NDC Package 62331-059-31

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Atovaquone powders is atovaquone is used to prevent or treat a serious lung infection called Pneumocystis pneumonia (PCP). This formulation utilizes a powder delivery system. Marketed by Divi's Laboratories Limited, this product is identified by NDC 62331-059.

Identification & Billing

NDC Package Code
62331-059-31
Package Description
22.5 kg in 1 DRUM
Product Code
62331-059
11-Digit Billing Format
62331005931

Clinical Specifications

Proprietary Name
Atovaquone
Non-Proprietary Name
Atovaquone
Substance Name
Atovaquone
Dosage Form
Powder - An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.
Active Ingredient(s)
ATOVAQUONE 1 kg/kg
Usage Information
Atovaquone is used to prevent or treat a serious lung infection called Pneumocystis pneumonia (PCP). This medication helps to stop infection symptoms such as fever, cough, tiredness, and shortness of breath.

Regulatory & Marketing

Labeler Name
Divi's Laboratories Limited
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
04-09-2007
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62331-059-31 identifies a specific commercial package of 22.5 kg in 1 drum of Atovaquone (UNFINISHED drug), a bulk ingredient labeled by Divi's Laboratories Limited. This powder is formulated for use and contains atovaquone as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Divi's Laboratories Limited on April 09, 2007. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Atovaquone is used to prevent or treat a serious lung infection called Pneumocystis pneumonia (PCP). This medication helps to stop infection symptoms such as fever, cough, tiredness, and shortness of breath.

How is this Divi's Laboratories Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62331005931. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62331-059-31
11-Digit CMS (5-4-2)
62331-0059-31

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.